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Background: Contrast-induced acute kidney injury (CI-AKI) occurs after the administration of intravenous iodinated
contrast agents. Oxidative stress has been proposed as one of the most important mechanisms in the pathogenesis
of CI-AKI. The objective of this study was to investigate the antioxidant effect of the extract from Phyllanthus emblica
(PE) in preventing CI-AKI.
Methods: Male Sprague Dawley rats were subjected into eight groups, were given water (control) or PE extract
(125 or 250 or 500 mg/kg/day) for 5 days before the induction of CI-AKI. Renal function and oxidative stress markers;
malondialdehyde (MDA), total antioxidant capacity (TAC), superoxide dismutase (SOD) and catalase (CAT) activity
were determined in plasma and renal tissue. Kidney sections were performed for histopathological examination.
Results: In the contrast media (CM) group, increases in blood urea nitrogen and serum creatinine were demonstrated
which correlated with severity of tubular necrosis, peritubular capillary congestion and interstitial edema. Moreover, an
increase in MDA and a decrease in TAC SOD and CAT activity in CM group were significantly changed when
compared with the control (P < 0.05). In contrast, CI-AKI-induced rats administrated with PE extract 250 and
500 mg/kg/day significantly preserved renal function and attenuated the severity of pathological damage (P < 0.05) as
well as significantly lower MDA and higher TAC, SOD and CAT than the CM group (P < 0.05).
Conclusions: This study demonstrated the protective role of PE extract against CI-AKI.
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Contrast-induced acute kidney injury (CI-AKI) is the
common iatrogenic cause of acute kidney injury (AKI)
following the use of intravenous contrast media (CM)
[1,2]. The incidence of CI-AKI is 1 to 2% in low risk pa-
tients with normal renal function but increases up to
25% in high risk patients with chronic renal impairment
or diabetes mellitus [2]. CI-AKI particularly in chronic
kidney disease patients increases the hospitalizations and
long term morbidity and mortality [3]. The pathogenesis
of CI-AKI is due to the ability of contrast agents could
induce renal vasoconstriction followed by hypoxic condi-
tion in the kidney which promotes further ischemic renal
injury by the increase of oxygen free-radicals through oxi-
dative stress [4]. Renal injury occurs when the hypoxic* Correspondence: adis_tasanarong@hotmail.com
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than antioxidant reservation in the renal tissue [5]. Many
strategies to prevent CI-AKI have been tested in many ex-
perimental studies and clinical trials. Hydration with iso-
tonic saline has been recommended to prevent CI-AKI
[6]. Additional antioxidants agents such as N-acetylcys-
teine, ascorbic acid and others demonstrated the conflict-
ing results to CI-AKI prevention [7-9].
Phyllanthus emblica (PE) also known as Amla or Indian
Gooseberry or Ma-Khaam-Pom in Thai is a natural fruit
that contains high concentrations of acorbic acid [10,11],
gallic acid [12], and mixture of phenolic compounds [13].
Active extracts of PE have been shown to posses antican-
cer [14,15], radioprotection [16], anti-inflammatory [17]
and antioxidant [18,19] properties in several models of
organ injury.
PE has never been used to assess its antioxidant effect
in CI-AKI. The present study was designed to investigate
the benefit of the PE extract in preventing CI-AKI andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Phyllantus embelica fruits collected from Ampor Marim,
Chiengmai Province Thailand on December 2011, were
dried by oven at 50°C. Dry plant material (10 kg) was
grinded and boiled in water for 30 min, filtered and
evaporated by evaporator. The extract was dried by
freeze dry as water extract of PE (PEW). The percentage
of yield obtained as 40.81%. The samples have been pre-
served in the refrigerator (−20°C). Authentication of
plant materials was identified by comparing against the
specimens deposited at the herbarium of Southern Cen-
ter of Thai Medicinal Plants, Faculty of Pharmaceutical
Science, Prince of Songkla University, Songkla, Thailand,
where herbarium vouchers have been kept (Herbarium
no.SKP 071160501).
Chemicals
Ascorbic acid, gallic acid and quercetin, thiobarbituric
acid (TBA), 2, 2’–azinobis (3-ethylbenzothia-zoline-6-
sulfonic acid) diammonium salt (ABTS), Trolox and all
other chemical reagents were purchased from Sigma-
Aldrich (Singapore). The low-osmolar, nonionic contrast-
media agent (Iopromide) was obtained from Schering AG
(Germany).
Preparing standard ascorbic acid, Gallic acid and
Quercetin
Ascorbic acid, Gallic acid and Quercetin were prepared as
concentration as 1 mg/ml. Ascorbic acid and quercetin
were prepared for 5 concentration per 1 millitre such as
6.25, 12.5, 25, 50 and 100 μg/ml. Gallic acid were also pre-
pared for 5 concentration per 1 millitre such as 25, 50,
100, 200 and 400 μg/ml. Injection for these standard com-
pounds for triplicate (N = 3).
Preparing for sample
Preparing PEW as concentration 10 mg/ml was filtrated
by syringe filter nylon, pore size 0.45 μm and injected in
High Performance Liquid Chromatography (HPLC) in-
strument by triplicate (N = 3).
HPLC analysis
The HPLC instrument is belong to Agilent Co. LTD
(LC1200) (USA), Column: Phenomenex® Luna 5 μ C18(2)
100A size 250x4.60 mm 5 micron, Mobile phase: 0.1%
Acetic acid in water (A): Methanol (B), gradient elution;
0–15 min as 5% B, 15–40 min as 80% B, 40–42 min as 5%
B and 42–45 as 5% B, Flow rate: 0.9 ml/min, Detection:
UV 280 nm, Injection volume: 20 μl.Animals
Male Sprague Dawley rats from the national animal center
(Mahidol University) were used. The experiments were
approved by the animal ethics committee of faculty of
medicine, Thammasat University. All rats were housed in
a temperature controlled room (24°C ± 1°C) and were
given standard food pellets and tap water until they
weighed 250-300 g, prior to the induction of CI-AKI. Rats
were divided into eight groups of 6 rats to each group as
follows: group 1, rats given sterile water (control); group
2, rats given sterile water followed by CI-AKI induction
(CM); group 3, rats given PE extract 125 mg/kg/day (PE
125 mg); group 4, rats given PE extract 125 mg/kg/day
followed by CM (PE 125 mg + CM), rats in both group 5
and group 6 given PE extract 250 mg/kg/day (PE 250 mg)
but in group 6 was followed by CM (PE 250 mg + CM),
group 7 and group 8 were given PE extract 500 mg/kg/day
(PE 500 mg) but group 8 was followed by CM (PE
500 mg + CM). PE or sterile water were orally adminis-
trated for 5 days, and then rats in Group 2, Group 4,
Group 6 and Group 8 were established with model of CI-
AKI on the next day. The day after CI-AKI induction, all
experimental animals were euthanized by inhalation of
ether anesthesia.
Introduction of CI-AKI in Rats
CI-AKI rats were subjected to CI-AKI protocol as de-
scribed [20-22] briefly; pentobarbital sodium (60 mg/kg)
anesthesia by intraperitoneal injection was followed by
CI-AKI induction, which was performed with drug ad-
ministration into tail vein. Drug administered consisted
of indomethacin at a dose of 10 mg/kg, followed at
15 min and 30 min later with Nw-nitro-L-Arginine me-
thyl ester (L-NAME) at dose of 10 mg/kg and with low-
osmolar, non-ionic contrast medium agent (Iopromide)
at a dose of 1600 mg iodine/kg. This quantity is the dose
of contrast medium that is standard for clinical use and
for other relevant experiments in rat models. As con-
trols, rats were injected with equivalent volume of saline
at each time.
Histopathologic examination of renal tissues
Both kidneys were excised immediately and cut into four
equatorial sections; they were then washed twice with
cold PBS. Two pieces of kidney were placed in 10% for-
maldehyde for histopathological examination. The other
pieces were flash-frozen in liquid nitrogen, and stored
at -70°C until used for subsequent tissue analysis.
Histological slides of the formalin-maintained samples
were prepared and counterstained with hematoxylin,
eosin (H&E) and periodic acid schiff staining (PAS). These
steps were then followed by semi-quantitative analysis the
kidney section by a pathologist functioning in a blind
manner [21,23,24]. Tubular necrosis and proteinaceous
Tasanarong et al. BMC Complementary and Alternative Medicine 2014, 14:138 Page 3 of 11
http://www.biomedcentral.com/1472-6882/14/138cast were graded according to a previous methodology as
follows: 0 = no damage; 1 =mild (unicellular, patchy iso-
lated damage); 2 =moderate (damage < 25%); 3 = severe
(damage between 25 and 50%) and 4 = very severe (>50%
damage). The degree of the medullary congestion was de-
fined as: 0 = no congestion; 1 =mild (vascular congestion
with identification erythrocytes by × 400 magnification);
2 = moderate (vascular congestion with identification of
erythrocytes by × 200 magnification); 3 = severe (vascular
congestion with identification of erythrocytes by × 100
magnifications) and 4 = very severe (vascular congestion
with identification of erythrocytes by × 40 magnifications).
Interstitial edema was graded as follows: 0 = no edema;
1 = mild (unicellular, patchy isolated edema); 2 = moder-
ate (edema < 25%); 3 = severe (edema between 25 and
50%) and 4 = very severe (>50% edema).
Biochemistry assay
In order to measure the oxidative stress markers includ-
ing the oxidation of lipids, the antioxidant enzyme, total
antioxidant capacity (TAC) and the renal function test,
the serum was separated from blood that had been ob-
tained from the heart and was kept at -20°C until used.
Renal function was investigated in serum blood urea ni-
trogen (BUN), and serum creatinine levels were deter-
mined using an automatic analyzer. All measurements
were performed using standard methods in a single,
hospital-based laboratory [25]. Also, oxidative stress
markers were measured in kidneys. Renal tissue samples
were prepared from 0.1 g of frozen renal tissue which
were homogenized in 1 ml of PBS (pH 7.2), and centri-
fuged at 10,000 g for 10 min at 4°C; supernatant was
then taken and kept at -80°C until used. Protein contents
in tissue homogenates were estimated by Bradford
method using bovine serum albumin as a standard.
Lipid peroxidation, in term of malondialdehyde (MDA)
was measured using thiobarbituric acid reactive sub-
stances (TBARS) assay, a method modified from that of
Wong et al. [26]. Briefly, 100 ml of serum or renal tissue
samples were subjected to 0.75 ml of phosphoric acid so-
lution (0.44 M) and incubated at room temperature for
10 min; 5 ml of TBA solution was then added. The mix-
tures were heated at 100°C for 30 min. The samples were
centrifuged at 4000 g for 10 min. The absorbance of the
supernatant was read at 532 nm. The concentration of
MDA was calculated from 0-20 μM of standard MDA
using 1,1,3,3 tetraethoxypropane. The results of the serum
or renal MDA were expressed as μM or μM per mg of
protein, respectively.
Total antioxidant capacity (TAC) was determined by
modified ABTS decolorization method as described by
Re et al. [27] ABTS (7 mM in final concentration), with
potassium per sulfate added (2.45 mM final concentra-
tion). The initial absorbance of induced ABTS radicalcation solution was approximately 0.7-0.02 at 734 nm.
After addition of 10 ml of sample or Trolox standard to
1 ml of diluted ABTS, the absorbance was measured at
734 nm after initial mixing. The TAC value was esti-
mated by the reduction of absorbance at 734 nm and
calculated against the curve of Trolox (0-1 μM). The
values of TAC were expressed in equivalence of μM Tro-
lox or Trolox/mg of protein, when measured in the
serum or renal tissue samples, respectively.
Renal superoxide dismutase (SOD) activity was also
determined using the SOD kit (Sigma), following the
manufacturing protocol. The SOD activity was measured
and expressed as units per mg protein.
Renal catalase (CAT) activity was measured according to
the modified method of Aebi et al. [28]. This method mea-
sures the exponential disappearance of H2O2 (10 mM) at
240 nm for 2 min at room temperature. The CAT activity
was expressed as units per milligram of protein (one unit of
catalase is equal to 1 μmol of H2O2 decomposition/min).
Statistical analysis
Results were present as the means ± SE. Student’s t-test
(when two groups were considered) and one-way ANOVA
were used to determine the significance of differences
in multiple group comparisons using SPSS software. A
p-value of less than 0.05 was considered to be as signifi-
cance. The area under the curve (AUC) was calculated
using the trapezoid rule. The correlation between two
continuous variables was assessed using Person’s correl-
ation coefficient and the coefficient of determination.
Results
HPLC analysis of PE
The five concentrations of ascorbic acid, gallic acid and
quercetin were calculated and plotted as correlation
graphs of concentration and AUC. The standard correl-
ation between the concentration and AUC of ascorbic
acid, gallic acid and quercetin were excellent, R2 = 0.999,
0.9998 and 0.9991 respectively. Figure 1A and B showed
the HPLC chromatograms of standard ascorbic acid,
gallic acid, quercetin and PE at UV 254, 370 and
280 nm. From HPLC analysis, the mean percentages of
ascorbic acid, gallic acid and quercetin in PE extract by
weight/weight were 0.00, 6.09 ± 0.38 and 0.68 ± 0.06
respectively.
Effect of PE extract on renal function parameters
Both BUN and serum Cr in the CM group were sig-
nificantly increased when compared with the control
(p < 0.05). While BUN was significantly decreased in
the PE extract 125 mg + CM group, PE extract 250 mg +
CM group and PE extract 500 mg + CM group when com-
pared with CM group (P < 0.05); Figure 2. In addition,
serum Cr was significantly decreased in only two of the
Figure 1 HPLC chromatogram of standard ascorbic acid, gallic acid and quercetin (1A) and PE extact (1B) at UV 254, 370 and 280 nm.
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Figure 2 Blood urea nitrogen and serum creatinine level in the eight experimental groups. # P < 0.05; compared to control, * P < 0.05;
compared to CM group.
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CM group when compared with CM group (P < 0.05);
Figure 2.
Effect of PE extract on attenuation of renal
histopathology
Histological evaluation of kidney sections in the CM
group revealed the significantly severe damage consist-
ing of tubular necrosis, proteinaceous cast formation,
PTC congestion and interstitial edema in the outer stripe
of the outer medulla (OSOM) and cortex when com-
pared with the control (P < 0.05); Table 1 and Figure 3.
Pretreatment with PE extract 250 mg and PE extract
500 mg in rats with CI-AKI induction were significantly
attenuated the development of these lesions whencompared with the CM group (P < 0.05); Table 1 and
Figure 3.
Effect of PE extract on attenuation of oxidative stress on
CI-AKI
The serum and renal MDA levels in the CM group were
significantly increased when compared with the control
(P < 0.05), whereas the MDA levels were significantly lower
in the PE extract 250 mg +CM group and PE extract
500 mg +CM when compared with CM group (P < 0.05);
Figures 4 and 5. The serum and renal TAC levels in the
CM group were significantly decreased when compared
with the control (P < 0.05), while the TAC levels in the
PE extract 250 mg + CM group and PE extract 500 mg +
CM group were significantly higher than the CM group
Table 1 Histopathological analysis of tubular necrosis, PTC congestion and interstitial edema in the five experimental
groups
Control (n = 6) CM (n = 6) CM PE 125 mg (n = 6) CM PE 250 mg (n = 6) CM PE 500 mg (n = 6)
Tubular necrosis and proteinaceous casts 0.1 ± 0.3 2.1 ± 0.5# 1.6 ± 0.5 1.3 ± 0.5* 0.7 ± 0.5*
PTC congestion 0.3 ± 0.5 2.3 ± 0.5# 2.1 ± 0.5 1.8 ± 0.4* 0.8 ± 0.4*
Interstitial edema and infiltration 0.2 ± 0.4 2.4 ± 0.5# 2.1 ± 0.5 1.8 ± 0.4* 0.8 ± 0.4*
The score of histopathological changes, such as scores of tubular necrosis and proteinaceous cast, PTC congestion, interstitial edema and infiltration, are presented
as means ± SD.
# P < 0.05; compared to control.
*P < 0.05; compared to CM.
CM: contrast media; PTC: peritubular capillaries.
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CAT levels were significantly decreased in CM group
when compared with the control (P < 0.05); Figure 5. The
renal SOD and CAT levels in the PE extract 125 mg +
CM, PE extract 250 mg +CM and PE extract 500 mg +
CM group were significantly higher than the CM group
(P < 0.05); Figure 5.
Discussion
To our knowledge, this is the first study to demonstrate
the renoprotective effect of PE extract to prevent the de-
velopment of renal dysfunction and pathological de-
struction as assessed by biochemical and markers of
oxidative stress in a rat model of CI-AKI. Prophylaxis
with PE extract at doses of 250 and 500 mg/kg/day
markedly suppressed renal tubular injuries and improved
antioxidant activity in CI-AKI rats.
The nephrotoxic effects of radiocontrast media have
been reported in many experimental studies [21,24,29]
and we followed the same methodology as reported else-
where [20,21,30]. The histopathological studies con-
firmed significant acute tubular necrosis, vacuolization,
loss of brush borders, proteinaceous cast formation and
interstitial edema were demonstrated similar to previous
studies in this nephropathy model [20,21,24,30]. We also
found that serum BUN and Cr levels increased signifi-
cantly in the CM group compared with the control
group, supporting the nephrotoxicity of radiocontrast
media to renal function. Pretreatment with PE extract
demonstrated clearly its renoprotetctive effect by attenuat-
ing the severity of renal pathological damage and improv-
ing renal function with the dose dependent renoprotective
effect of PE extract.
Oxidative stress has been proposed as one of the most
important mechanisms in the pathogenesis of CI-AKI
[31]. In vitro and in vivo studies demonstrate clearly that
iodinated contrast media administration enhances hyp-
oxia and increases the production of ROS within the
kidney [21,24,32]. Lipid peroxidation is initiated as a re-
sult of the ROS induced abstraction of hydrogen in cel-
lular membranes, which results in the formation of
relatively stable compounds such as MDA. The produc-
tion of free radicals is blocked by endogenousantioxidant systems such as TAC, SOD and CAT en-
zymes [21,24]. Thus, oxidative stress induced by contrast
media during AKI is a relative excess of oxidants caused
by increased free radical production and/or decreased
antioxidant defense systems [20,21,24]. In the present
study, increased MDA and decreased TAC, SOD and
CAT enzyme activities in serum and renal tissues ex-
posed to CM suggests that these enzymes were con-
sumed due to increased oxidative stress. Decreased SOD
and CAT scavenger activities results in higher H2O2 con-
centration and explains the change in the level of MDA
during CI-AKI. The higher of antioxidant enzyme SOD
and CAT activities and lower MDA in the PE extract
pretreatment might be a response for renal injury after
contrast administration. Thus, rats that receive PE ex-
tract before CM had decreased MDA and increased
SOD and CAT activities in renal tissues could protected
against CI-AKI from ROS. Moreover, the increased
MDA and decreased TAC in rat plasma that exposed to
CM reflect an increase in lipid peroxidation and de-
crease antioxidation in the systemic response. Thus, de-
creasing oxidative stress injury following PE extract
application has been associated with antioxidant effects
in circulation system.
Current recommendations to decrease the incidence
of CI-AKI in high risk patients are hydration with saline,
use of iso-osmolar contrast agents, minimum volume of
contrast media, and avoiding nephrotoxic drugs [6,33].
Recent studies try to use antioxidants as protective rem-
edies against CI-AKI have yielded conflicting results
[34-36]. Antioxidant effect of PE was demonstrated
in vitro and vivo studies by increased the concentration
of antioxidant enzymes SOD and CAT and decreased
MDA in lipid peroxidation [37-39]. The present study
demonstrated that antioxidant effect of PE extract could
decrease MDA in both plasma and renal tissues. More-
over, PE extract preserved plasma TAC and renal tissues
TAC, SOD and CAT activities. These effects correlated
with the attenuation of histopathological injury from
contrast media administration. The dose dependent ef-
fect of PE extract started at dose 250 mg/kg/d and had
the additional effect at dose 500 mg/kg/d similar to the
antioxidant effect of vitamin E in the experimental study
Figure 3 Histopathological with H& E staining of CI-AKI in rats. A and B show normal rat kidneys in the cortex and medulla. Rats induced
with CM (C and D) demonstrate severe TEC necrosis, moderate PTC congestion (black arrows) and proteinaceous casts (green arrows) in the
cortex and medulla. Rats induced with CM and pre-treatment with PE extract 250 mg/kg/day (E and F) show a decrease in the severity of TEC
necrosis, PTC congestion, and proteinaceous casts in the cortex and medulla. Interestingly, rats induced with CM and pre-treatment with PE
extract 500 mg/kg/day (G and H) demonstrate minimal TEC necrosis, PTC congestion or proteinaceous casts in the cortex and medulla, similar to
control-rat kidneys. (Magnifications: ×400 in A-H). CM: contrast media; PTC: peritubular capillaries; TEC: tubular epithelial cells.
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Figure 4 Plasma MDA and TAC level in the eight experimental groups. # P < 0.05; compared to control, *P < 0.05; compared to CM group.
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effect of PE extract could prevent CI-AKI through anti-
oxidant property.
Phyllanthus emblica is widely used in Thai traditional
medicine and Ayurvedic Medicine for treatment of vari-
ous diseases. The fruit of PE is known as a rich source
of ascorbic acid [10,11], gallic acid [12], and also con-
tains a mixture of phenolic compounds [13]. The major
substrate which acts to be antioxidant in PE is gallic
acid, vitamin C and others depending on the technique
that separates the compound from PE [41,42]. From the
process to prepared PE extract in the present study,
plant was dried by oven at 50°C before grinded and
boiled in water. In general, vitamin C was destroyed by
heat that could be loss from the preparing process [43].
In addition, PE extract by HPLC analysis in the presentstudy showed the main substrate was gallic acid. Gallic
acid is a polyphenolic compound with multiple hydroxyl
groups which are able to donate its proton to break the
chain reaction of free radicals consequently as a lipid
peroxidation inhibitor [44,45]. Moreover, gallic acid was
demonstrated as an excellent antioxidant with high free
radical scavenging effect [45,46]. From the experimental
studies, gallic acid was demonstrated to prevent or at-
tenuate the severity of brain, heart and liver damage
from ischemic or toxic substances injury [47-49]. Fur-
thermore, the reno-protective effect of gallic acid from
antioxidant and antiinflammation properties was dem-
onstrated in many experimental studies in AKI against
lindane [49], ferric nitriloacetic acid [50], and sodium
fluoride [47] and chronic kidney disease [51]. By our
HPLC analysis, gallic acid was present in 6% of the PE
Figure 5 Renal tissue MDA, TAC, SOD and CAT level in the eight experimental groups. # P < 0.05; compared to control, *P < 0.05;
compared to CM group.
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the 250 and 500 mg/kg/d of PE extracts, respectively.
These doses of gallic acid could be the basis of human
studies. Thus PE extract administration could prevent
CI-AKI in rats with antioxidant effect from gallic acid.
These finding could be assessed in patients with high
risk CI-AKI in the future clinical trials.
The plasma levels of PE extract and the accumulation
of PE extract on renal tissues with the repeated daily
dose may be higher than the single dose administration.
In experimental study, the bioavailability of gallic acid
from grape seed polyphenol extract is improved by re-
peated dosing in rats [52]. The single dose with oral ad-
ministration demonstrated that the intestinal absorption
of gallic acid is poor (<2%). While repeated exposure to
the extract has shown the absorption of gallic acid was
significantly higher than single dose treatment and
reached to tissues level at day 10. Moreover, two gallic
acid-derived compounds isolated from Casearia sylves-
tris leaves could reverse NK cell cytolysis which was sup-
pressed from tumor growth when mice were treated
with these compounds for 4 days [53]. In contrast, a sin-
gle dose administration with a large volume and high
concentration of any compound via oral route may cause
adverse effects and could not reach to the therapeutic
levels in the tissues. From these informations, we make
the decision to give PE extract orally as presented in the
protocol. However, a high dose administration of PE ex-
tract for 2 or 3 days before contrast administration
should be evaluated for the preventing CI-AKI.
Study limitations
Monitoring of urine output and/or novel biomarker in
plasma or urine is a much better indicator for early diag-
nosis of CI-AKI. However, we have measured only
serum BUN and Cr levels. Also, we have only H&E and
PAS staining for histopathologic examination of renal
tissues. Therefore, the immunohistochemistry staining
such as Tunnel or PCNA and the evaluation of protein
and gene expression in apoptosis or inflammatory path-
way should be prepared to confirm CI-AKI.
Conclusion
The present study suggests that PE extract administra-
tion pretreatment for five days in dose 250 and 500 mg/
kg/day before the induction of CI-AKI exerts significant
renoprotective effects in a rat model of CI-AKI. These
finding indicate that PE extract could represent a novel
and effective preventive approach for CI-AKI as a result
of its antioxidant capacity to preserve renal function and
directly protect renal tissues. Investigation with add-
itional experimental studies and clinical trials is required
to confirm to the advantage of PE extract to prevent the
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